Clinical Trials Browser

Graft vs Host Disease × carfilzomib × Plasma cell × Clear all

NCT02145403 2022-01-03

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

Phase 1/2 Completed

53 enrolled 17 charts

LymphoidOther hematologic neoplasmPlasma cell

Graft vs Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Recurrence, Hematologic Neoplasms